Conexeu Targets $2 Billion Aesthetics Opportunity with GLP-1-Driven Demand
Event summary
- Conexeu completed its 12-month P.R.O.O.F. study evaluating CXU™ for large-volume body restoration, a category projected to reach $2 billion by 2030.
- The breast implant market is expected to grow from $2.21 billion in 2025 to $3.21 billion by 2030, while the buttock augmentation market could expand to $11.72 billion by 2030.
- Conexeu aims to submit a 510(k) application for CXU™ in Q1 2027, targeting large-volume injectable aesthetics as a first mover.
The big picture
Conexeu is positioning itself as the first mover in large-volume injectable aesthetics, capitalizing on the unmet demand created by GLP-1 weight loss treatments. The company’s CXU™ platform aims to address a gap left by traditional fillers and surgical options, with projections suggesting significant market expansion. Success hinges on regulatory approval and execution against competitors already exploring similar opportunities.
What we're watching
- Regulatory Pathway
- Whether Conexeu can secure a 510(k) submission in Q1 2027 and navigate FDA requirements for its investigational device.
- Market Adoption
- The pace at which GLP-1-related aesthetic demand will drive revenue growth, projected to triple from $0.7 billion to $2.0 billion by 2030.
- Competitive Positioning
- How Conexeu’s CXU™ platform will differentiate itself in a market dominated by established players like AbbVie and Galderma.
Related topics